Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Benitec Biopharma (BNTC) EBITDA (2019 - 2025)

Benitec Biopharma (BNTC) has disclosed EBITDA for 7 consecutive years, with -$8.9 million as the latest value for Q2 2025.

  • Quarterly EBITDA fell 86.9% to -$8.9 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$35.7 million through Jun 2025, down 63.52% year-over-year, with the annual reading at -$37.9 million for FY2025, 73.58% down from the prior year.
  • EBITDA hit -$8.9 million in Q2 2025 for Benitec Biopharma, up from -$14.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$3.5 million in Q1 2022 to a low of -$14.5 million in Q1 2025.
  • Historically, EBITDA has averaged -$5.7 million across 5 years, with a median of -$4.8 million in 2021.
  • Biggest five-year swings in EBITDA: rose 12.6% in 2024 and later crashed 249.09% in 2025.
  • Year by year, EBITDA stood at -$4.9 million in 2021, then fell by 14.21% to -$5.6 million in 2022, then fell by 25.11% to -$7.0 million in 2023, then dropped by 1.18% to -$7.1 million in 2024, then fell by 26.6% to -$8.9 million in 2025.
  • Business Quant data shows EBITDA for BNTC at -$8.9 million in Q2 2025, -$14.5 million in Q1 2025, and -$7.1 million in Q4 2024.